[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352533-105":59,"doc-detail-352533-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","multiomics-profiling-reveals-distinct-immunosuppression-and-metabolic-dysregulation-in-aggressive-subtypes-of-thyroid-cancer","Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer","","Using 4D-DIA proteomics integrated with total transcriptomics on 120 FFPE thyroid tumors, the study maps molecular programs across papillary (PTC), poorly differentiated (PDTC), and anaplastic (ATC) subtypes. ATC shows heightened immune surveillance/evasion alongside suppressed fatty-acid and OXPHOS metabolism, while PDTC features glycolysis-biased metabolic rewiring. The study nominates FCGR2A as a protein biomarker of aggressive disease and validates signals through IHC (n=28), public bulk RNA datasets, and single-cell analyses. Results refine thyroid cancer taxonomy and highlight actionable immune–metabolic vulnerabilities.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multiomics-profiling-reveals-distinct-immunosuppression-and-metabolic-dysregulation-in-aggressive-subtypes-of-thyroid-cancer/352533/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multiomics-profiling-reveals-distinct-immunosuppression-and-metabolic-dysregulation-in-aggressive-subtypes-of-thyroid-cancer/352533.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What data types and sample numbers were used to study thyroid cancer subtypes?","Question",{"text":113,"@type":114},"The analysis integrated 4D-DIA proteomics and total transcriptomics across 120 FFPE thyroid tumor samples. Proteomics covered 118 tumors and transcriptomics covered 69 samples, with matched adjacent normal tissues.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do ATC and PDTC differ in immune and metabolic programs?",{"text":118,"@type":114},"ATC exhibits enhanced immune surveillance/evasion with suppressed fatty-acid and OXPHOS metabolism. PDTC shows glycolysis-biased metabolic rewiring and distinct immune landscapes compared with ATC.",{"name":120,"@type":111,"acceptedAnswer":121},"What is FCGR2A (CD32) in the context of this study?",{"text":122,"@type":114},"FCGR2A is nominated as a protein biomarker associated with aggressive disease. The study validates key signals using IHC (n=28) and corroborates findings with public bulk RNA and single-cell data.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352533,1790247749,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer  \nAuthors  \nShanying Gui, Kate Huang, Jianling Qiang, Yunzhao Chen, Meifu Gan, Zhaochang Jiang, Jiazi Qian, Chenchen Yi, Yi Ding, Huihui Jiang, Fulong Zheng, Wanlin Lei, Lulu Jin, Xiaowei Zhang, Hezhi Fang, and Maofeng Wang  \nCorrespondence  \n[fangh@cicams.ac.cn](fangh@cicams.ac.cn) ; [wzmcwmf@wmu.edu.cn](wzmcwmf@wmu.edu.cn)  \nIn Brief  \nUsing 4D-DIA proteomics integrated with total transcriptomics on 120 FFPE thyroid tumors, we chart molecular programs across PTC → PDTC →ATC. ATC shows heightened immune surveillance/evasion with suppressed fatty-acid/OXPHOS metabolism, whereas PDTC exhibits glycolysis-biased rewiring. We nominate the myeloid receptor FCGR2A as a protein biomarker of aggressive disease and validate key signals by IHC (n = 28), public bulk RNA sets, and single-cell data. These findings refine thyroid cancer taxonomy and suggest actionable immune–metabolic vulnerabilities.  \nGraphical Abstract  \nHighlights  \n• Largest multicentered ATC/PDTC cohort for multi-omics analysis.  \n• First 4D-DIA proteomic profiling of ATC/PDTC clinical samples.  \n• Aggressive molecular features and immunosuppressive TME in ATC/PDTC.  \n• FCGR2A (CD32) identified as a biomarker for ATC/PDTC.  \n2026, Mol Cell Proteomics 25(3), 101513  \n© 2026 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY license ([http://creativecommons.org/](http://creativecommons.org/)[ ](http://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)).  \n[https://doi.org/10.1016/j.mcpro.2026.101513](https://doi.org/10.1016/j.mcpro.2026.101513)  \n RESEARCH  \nMultiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer  \nShanying Gui 1 ,‡ , Kate Huang2 ,‡, Jianling Qiang3 ,‡, Yunzhao Chen4 ,‡, Meifu Gan5 ,‡, Zhaochang Jiang6, Jiazi Qian7, Chenchen Yi7 , Yi Ding7, Huihui Jiang7, Fulong Zheng7, Wanlin Lei3, Lulu Jin3, Xiaowei Zhang8, Hezhi Fang7 ,9 ,* , and Maofeng Wang3 ,*  \nThyroid cancer comprises a heterogeneous group of malignancies with distinct clinical outcomes and molecular features, including papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). This study aimed to delineate the molecular and immune landscapes of these subtypes and identify potential biomarkers for the aggressive forms, ATC and PDTC. We assembled a wellannotated cohort of 120 formalin-fixed paraffinembedded samples, including 35 ATC, 18 PDTC, 37 PTC cases, and 30 adjacent normal tissues (N) paired with PTC, collected over the past decade from multiple hospitals. To our knowledge, this represents the largest clinical ATC/ PDTC cohort subjected to multiomics profiling and the first comprehensive proteomic analysis of these aggressive thyroid cancers. Using 4D–data-independent acquisition proteomics on 118 tumors (ATC 34, PDTC 18, PTC 36, and N 30), integrated with total RNA-seq on 69 samples (ATC 10, PDTC 5, PTC 31, and N 23), we revealed substantial molecular similarities between ATC and PDTC, both markedly distinct from PTC and adjacent normal tissues. ATC and PDTC exhibited significant enrichment in immune-related and metabolic pathways, with transcriptomic data indicating aggressive phenotypes and pronounced immunosuppression. Distinct immune landscapes of ATC and PDTC were revealed with neutrophil extracellular trap formation and M0 macrophage accumulation as key immunosuppressive mechanisms. Notably, Fc  \nfragment of IgG receptor IIa (CD32) was identified as a promising biomarker for ATC, implicating a functional link between immune evasion and tumor aggressiveness. Our findings provide a comprehensive molecular and immunological characterization of thyroid cancer subtypes, offering novel insights into the pathogenesis of ATC and","cbCaigEdy4hTrLYu","https://ap.wps.com/l/cbCaigEdy4hTrLYu","pdf",11643923,16,"English","# In Brief\n# Graphical Abstract\n# Highlights\n# Research Overview\n## Cohort and Multiomics Design\n## Immune and Metabolic Findings\n## Biomarker Identification (FCGR2A)\n# Background: Thyroid Cancer Subtypes and Need for Mechanistic Insight","[{\"question\":\"What data types and sample numbers were used to study thyroid cancer subtypes?\",\"answer\":\"The analysis integrated 4D-DIA proteomics and total transcriptomics across 120 FFPE thyroid tumor samples. Proteomics covered 118 tumors and transcriptomics covered 69 samples, with matched adjacent normal tissues.\"},{\"question\":\"How do ATC and PDTC differ in immune and metabolic programs?\",\"answer\":\"ATC exhibits enhanced immune surveillance/evasion with suppressed fatty-acid and OXPHOS metabolism. PDTC shows glycolysis-biased metabolic rewiring and distinct immune landscapes compared with ATC.\"},{\"question\":\"What is FCGR2A (CD32) in the context of this study?\",\"answer\":\"FCGR2A is nominated as a protein biomarker associated with aggressive disease. The study validates key signals using IHC (n=28) and corroborates findings with public bulk RNA and single-cell data.\"}]","Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer | PDF",1790100130,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/063a71f2c5362d542c68937c6bcf9c53.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ce7018703934b75abdbb4128a5f4f01.webp",982,1294,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c23500b05acab04be6ebf9d93958f6b0.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66e626bac2f2254cbc6721f5ff292abf.webp",980,1292]